To The Moon

Selling covered call options (sell covered call) is a strategy adopted by many large funds. It can also be used by retail investors in the US stock market.You can get income while holding it. This strategy is very suitable for stocks that have long-term positions, but they have not moved but they are not in a bearish position recently or are in a bearish position recently. It can be a good strategy for mature investors to roll over when holding some targets for a long time. Income comparison Assume that investors hold 200 shares of Amazon from January 1 to December 17, 2021 If there is no operation during the holding period, the final total assets will be USD 675,484 If the covered call strategy is carried out, it will be operated once a week; if 100 shares are sold after the exercise, ano

Singapore was rocked by news that a cabinet minister and a property tycoon were arrested in one of the most serious graft cases in nearly four decades.Allegations of corruption and other misconduct by senior ruling party officials are rare in Singapore. Do you have any comments on this investigation?Speculation about the investigation rippled through social media, and the local officials rushed to reiterate their zero-tolerance stance on graft and assure citizens they would conduct a thorough investigation. www.cpib.gov.sgSingapore Prime Minister Lee Hsien Loong said on the Facebook on 12th that he had instructed Transport Minister S. Iswaran to take leave of absence until the investigation is completed.Facebook of Lee Hsein LoongBrief introduction of S.Iwaran: Born in 1962, Indian ethnici

1. $BridgeBio Pharma, Inc.(BBIO)$ +75.85%: analysts are positive on upbeat results from heart drug trial BridgeBio, a pharmaceutical company, experienced a significant surge in its stock price, rising as much as 70% in response to positive results from a late-stage trial of its cardiovascular disease treatment. According to a Mizuho analyst, the trial results surpassed even the most optimistic scenarios anticipated by the market.Mizuho's Salim Syed, who has a "buy" rating on the stock and a price target of $29, praised the trial data, describing it as "super clean and very consistent across measures." Based on the positive trial data, he believes that the stock has the potential to reach levels above $40.Additionally, Raymond James analy